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Abstract
Background
In asthma management guidelines the primary goal of treatment is asthma control. To date,
asthma control, guided by symptoms and lung function, is not optimal in many children and
adults. Direct monitoring of airway inflammation in exhaled breath may improve asthma
control and reduce the number of exacerbations.
Aim
1) To study the use of fractional exhaled nitric oxide (FeNO) and inflammatory markers in
exhaled breath condensate (EBC), in the prediction of asthma exacerbations in a pediatric
population. 2) To study the predictive power of these exhaled inflammatory markers com-
bined with clinical parameters.
Methods
96 asthmatic children were included in this one-year prospective observational study, with
clinical visits every 2 months. Between visits, daily symptom scores and lung function were
recorded using a home monitor. During clinical visits, asthma control and FeNO were as-
sessed. Furthermore, lung function measurements were performed and EBC was collected.
Statistical analysis was performed using a test dataset and validation dataset for 1) condi-
tionally specified models, receiver operating characteristic-curves (ROC-curves); 2) k-near-
est neighbors algorithm.
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Results
Three conditionally specified predictive models were constructed. Model 1 included inflam-
matory markers in EBC alone, model 2 included FeNO plus clinical characteristics and the
ACQ score, and model 3 included all the predictors used in model 1 and 2. The area under
the ROC-curves was estimated as 47%, 54% and 59% for models 1, 2 and 3 respectively.
The k-nearest neighbors predictive algorithm, using the information of all the variables in
model 3, produced correct predictions for 52% of the exacerbations in the validation
dataset.
Conclusion
The predictive power of FeNO and inflammatory markers in EBC for prediction of an asthma
exacerbation was low, even when combined with clinical characteristics and symptoms.
Qualitative improvement of the chemical analysis of EBC may lead to a better non-invasive
prediction of asthma exacerbations.
Introduction
Asthma is the most common chronic inflammatory disorder in children [1]. Worldwide epide-
miological studies show that asthma is still not optimally controlled in many children and
adults, despite proper pharmacotherapy and emphasis on asthma control in international asth-
ma management guidelines [2–6]. Asthma control is determined by clinical symptoms, lung
function, and occurrence of asthma exacerbations [2–4]. Exacerbations are accompanied by
loss of quality of life, higher costs due to extra clinical visits and absence from school and work
[7].
Currently, management of asthma and titration of treatment is based on the level of asthma
control determined by symptoms and lung function [2–4]. However, these measures of asthma
control do not give direct insight into the underlying inflammatory process. Measures of air-
way inflammation such as fractional exhaled nitric oxide (FeNO) and biomarkers in exhaled
breath condensate (EBC) reflect airway inflammation in a non-invasive manner. This is in con-
trast with an invasive procedure such as bronchoscopy with assessment of inflammatory mark-
ers in bronchial alveolar lavage or biopsies [8]. These procedures are too invasive for routine
and repeated use (in children). It is hypothesized that the management of asthma may improve
by monitoring of airway inflammation and by titration of treatment on basis of inflammatory
parameters in exhaled breath [9, 10].
In a previous longitudinal study in 40 children with asthma, exacerbations were predicted
by Interleukin 5 (IL-5) in EBC and acidity of EBC (Inflammation Asthma Monitoring,
FLAME-study) [9]. FeNO is an exhaled marker of inflammation, which reflects eosinophilic
airway inflammation [11]. So far, titration of medication based on FeNO has not been associat-
ed with significant decrease in the number of exacerbations [11–13]. However, 1 study was un-
derpowered, which may have contributed to this finding. Moreover, the predictive value of
FeNO for an asthma exacerbation may improve, when combined with clinical characteristics
and other exhaled markers of inflammation.
Before this concept of treating asthmatic children based on these exhaled markers of inflam-
mation can be tested in a clinical randomized controlled trial (RCT), the accuracy of this meth-
od should be confirmed in a new population. Therefore, the aims of this study are: 1) To assess
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the predictive power of FeNO and inflammatory markers in EBC, and their combination for
asthma exacerbations in a pediatric population. 2) To assess the predictive power for asthma
exacerbations of exhaled markers of inflammation combined with clinical characteristics such
as atopy, bronchial hyperresponsiveness, reversibility to a bronchodilator, asthma control, and
daily dosage of inhaled corticosteroids (ICS).
Methods
Study design and patients
Children between 6 and 18 years old with doctor-diagnosed asthma were recruited for this one
year observational cohort study (clinicaltrial.gov NCT 01239238). All children had been treated
for asthma at the outpatient clinic of 2 specialized pediatric pulmonology centers for at least 6
months and used inhaled corticosteroids during the year preceding the study. Asthma was de-
fined by the criteria of the Global Initiative for Asthma (GINA) and the guideline of the Dutch
Society of Pediatrics as: 1) presence of asthma symptoms and use of ICS during the year pre-
ceding the study [2, 4]; 2) reversibility to a β2-agonist defined as an increase in FEV1 of 9% of
predicted value [4, 14], as described before [9]; and/or 3) presence of bronchial hyperrespon-
siveness (defined as a> 20% drop in FEV1 after the inhalation of histamine with a concentra-
tion 8 mg/ml) [4]. Exclusion criteria were: 1) technical unsatisfactory performance of lung
function measurements, 2) presence of cardiac abnormalities, 3) mental retardation, 4) con-
genital abnormalities or existence of a syndrome, 5) active smoking, or 6) treatment with im-
munotherapy during the study.
During the study, the investigators were blinded for the study results. The parents received
financial compensation for transportation costs to the clinic. The recruitment of patients
started in November 2010 and the follow-up ended March 2013.
The Medical Ethical Committee of the Maastricht University Medical Centre approved this
study. Informed consent was signed by all parents and by children aged 12 years and older.
Study parameters and procedures
The primary outcome measure was the occurrence of an exacerbation. Regular clinical visits
took place every 2 months. During each clinical visit, the same measurements and sequence of
procedures took place. All measurements were performed by 3 trained research nurses. First,
children completed the Asthma Control Questionnaires (ACQ). FeNO assessment, EBC collec-
tion, and dynamic spirometry were then performed (Table 1). Between clinical visits, daily
home monitor assessments were performed by the children and electronic questionnaires were
completed by the parents.
Questionnaires
The ACQ was used to assess asthma control at the clinical visits [15]. The cut-off points used
for level of asthma control were: ACQ 0.75 (controlled asthma); 0.75<ACQ1.5 (partly
controlled); and ACQ>1.5 (uncontrolled asthma). The ACQ results were not used in the treat-
ment protocol. Treatment (step-up/step-down) was based on asthma control using the GINA-
criteria [2]. For this purpose, the GINA-respiratory symptoms during the 2 weeks preceding
clinical visits and lung function parameters during clinical visits were used.
FeNO assessment
FeNO was measured online using a NIOX analyzer (Aerocrine, Solna, Sweden) according to
American Thoracic Society/European Respiratory Society (ATS/ERS) criteria [16]. The
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animation as provided by the manufacturer was used to support children to establish a stable
airflow during the maneuver. A standard flow rate of 50 ± 5 ml/sec was required for a
correct maneuver.
EBC collection, storage and chemical analysis
EBC was collected by means of an optimized borosilicate glass tube, cooled by circulating water
of 0.7 degrees Celsius, as reported previously [17]. Children breathed for 10 minutes into the
tube, through a mouthpiece connected to a two way non-rebreathing (series 1420; Hans Rudolph
Inc, Kansas City, USA) valve, which also served as a saliva trap. The child used a nose-clip,
breathed tidally and was entertained by a movie or game. Acidity of the condensate was mea-
sured without de-aeration, immediately after collection (handheld pH-meter, typePH1000H,
and mic-micro-S7 pH sensor, VWR International B.V., NL, Germany). The EBC-samples were
separated into aliquots and immediately frozen using dry ice and stored at −80 degrees Celsius.
From collection to chemical analysis freeze-thaw cycles were avoided [18]. For chemical analysis
1 sample of at least 60μL was thawed. The levels of interleukin (IL) 1α, IL-5, IL-6, IL-8, IL-13, IL-
17 and tumor necrosis factor (TNF) α were determined using a commercially available high sen-
sitivity bead-based flow immunoassays and concentrations were calculated using BioPlex soft-
ware version 5.1 (Millipore, St Charles, MO, USA). The calibration line consisted of the
calibration fluids that were added to the plate according to the manufacturer’s protocol plus 2 se-
quential dilutions to decrease the lower limit of quantification (LLoQ) of the assay. The median
LLoQ’s assessed during analysis of the EBC samples were for IL-1α: 636 fg/ml, IL-5: 13 fg/ml,
IL-6: 112 fg/ml, IL-8: 25 fg/ml, IL-13: 30 fg/ml, IL-17: 575 fg/ml and TNFα: 23 fg/ml.
Concentrations of samples were calculated by extrapolation when fluorescence indices were
below the LLoQ, yet above background. If outcomes could not be extrapolated, a concentration
of 50% of the lowest measured concentration for the specific marker was imputed like de-
scribed previously [17].
Dynamic spirometry
Dynamic spirometry was performed by means of the ZAN 100 spirometer, according to ATS/
ERS standards (nSpire Health GmbH, Oberthulba, Germany) [19]. The highest value of 3
Table 1. Overview of study parameters.
Visit 0 months 2 months 4 months 6 months 8 months 10 months 12 months
ACQ • • • • • • •
GINA symptom score* • • • • • • •
FeNO • • • • • • •
EBC collection • • • • • • •
Dynamic spirometry • • • • • • •
PC20 test At the start of the study
Registration of exacerbations During the entire study
Home monitoring† During the entire study
ACQ = Asthma Control Questionnaire, GINA = Global Initiative for Asthma, FeNO = Fractional exhaled Nitric Oxide, EBC = exhaled breath condensate,
PC20 = histamine bronchial hyperresponsiveness test.
* Symptom score based on GINA criteria was collected during 2 weeks preceding the clinical visit. This score was combined with FEV1, to assess asthma
control as deﬁned by GINA.
† Home monitoring consisted of daily symptom score plus FEV1 measurements.
doi:10.1371/journal.pone.0119434.t001
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correctly performed maneuvers was used for analysis. Recorded parameters included: FEV1,
forced vital capacity (FVC) and maximum expiratory flow at 50% of FVC (MEF50), all express-
ed as a percentage of the predicted value. Subsequently, the patient inhaled 400 μg salbutamol
by means of a spacer. After 15 minutes, a second lung function test was performed in order to
assess the reversibility to a β2-agonist. Patients were instructed to stop short-acting bronchodi-
lators at least 8 hours and long-acting bronchodilators at least 48 hours before testing.
Bronchial hyperresponsiveness
Bronchial hyperresponsiveness was evaluated at the start of the study by a bronchial histamine
challenge test [20]. At first, an aerosol of buffered saline was inhaled, followed by aerosols of
histamine solutions with doubling concentrations from 0.03 mg/mL to 16mg/mL, at intervals
of 5 minutes. After complete inhalation of a solution, the FEV1 was measured at 30, 90 and
120 seconds. The percentage decline in FEV1 was calculated and the test was stopped when a
drop of 20% or more in FEV1 occurred, or the highest concentration of 16 mg/mL histamine
was administered. The PC20 was calculated from a log concentration versus dose response
curve. After reaching the threshold, children inhaled 800 microgram salbutamol, followed by
3 Maximal Expiratory Flow Volume maneuvers. 16% of the PC20 tests were missing, because of
recurrent active airway infections, inability to stop antihistamines or bronchodilators, or cali-
bration errors of the histamine nebulizer.
Atopy
Atopy was defined by either a positive Phadiatop (Phadia, Uppsala, Sweden) or RAST (Phar-
macia, Uppsala, Sweden) or Allergen Skin test. In 3% of the children allergy tests were missing.
Homemonitoring
Daily home monitoring was performed using an AM2+ home monitor (Jaeger, CareFusion,
Houten, The Netherlands). Participants were asked to use the home monitor on a daily basis at
approximately the same time of the day and were carefully and repeatedly instructed. The
AM2+ home monitor is a hand held monitor that can store respiratory symptom scores and
lung function measurements. The respiratory symptom score consisted of a short question-
naire including asthma symptoms based on the GINA-criteria for asthma control. The lung
function measurements consisted of 3 maneuvers with maximal effort to achieve FEV1. The
highest FEV1 value of each day was selected for each patient. The data were transferred into a
secured portal twice a week.
Definition of asthma exacerbations
Moderate or severe asthma exacerbations were defined according to the latest ATS/ERS criteria
[21].
Asthma treatment protocol during study
Asthma medication was titrated based on GINA asthma level of control, according to GINA
guidelines and the guideline of the Pediatric Pulmonology section of the Dutch Society of Pedi-
atrics [2, 4]. In the adjustment of treatment, FeNO values, markers in EBC or home monitor
results were not taken into account.
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Sample size calculation
The criterion for sample size calculation was reliable estimation of sensitivity and specificity of
the predictive model. We considered a maximum estimation error of sensitivity or specificity
of 0.15. The corresponding standard error is 0.075 (Maximal SE = 2SE; Max SE = 0.15/2 =
0.075). We expected a true risk of exacerbation of 45%, based on the previous FLAME-study
[9]. This resulted in inclusion of at least 91 children (SE = sqrt (p(1-p)/N), where p = true sen-
sitivity or specificity, N = sample size for that group). We assumed a dropout rate of 10% dur-
ing 1 year follow-up, so we aimed to include at least 100 children.
Statistical data analysis
All the statistical analyses were carried out using the SAS software package version 9.2. In the
explanatory analysis of the data numerical variables were summarized using means and stan-
dard deviations (SD), or medians and Inter Quartile Ranges (IQR, i.e. 25th–75th percentile).
Furthermore, categorical variables were summarized using frequency tables and percentages.
Due to the longitudinal nature of the study, responses from the same patient are naturally
correlated. To account for this correlation conditional models were used. Conditional models
describe the current outcome of a patient, in a sequence of longitudinal measurements, condi-
tional upon (subsets of) the previous outcomes and covariates [22]. In the present study the
probability of an asthma exacerbation between the current and next visit was modeled using 3
conditional models. The first model used the 8 cytokines in EBC (IL-1α, IL-5, IL-6, IL-8, IL-13,
IL-17, TNFα), sex, age, trial center and the occurrence (or not) of an exacerbation in the period
between the previous and current visit, as covariates. In the second model, FeNO, reversibility
to a bronchodilator as increase in FEV1% of predicted value, PC20, daily dosage of ICS, atopy,
ACQ score, sex, age and trial center and the occurrence (or not) of an exacerbation in the peri-
od between the previous and current visit were used as covariates. In the third model, the co-
variates from the first and second model were combined. The models were fitted using the
procedure GENMOD in SAS.
For the analysis 11 randomly selected patients (76 measurements) were used to create a vali-
dation dataset and measurements (n = 543) of all the remaining patients were included in a
training dataset. All predictive models were estimated using the information in the training
dataset. Posteriorly the predictive capability of inflammation markers was assessed using the
information in the validation dataset. The predictive capability of the models was primarily
evaluated using the area under the corresponding ROC-curves. Additionally, the percentage of
correct predictions was also assessed using the validation data.
Alternatively, the k-nearest neighbors algorithm (KNN) was also used to evaluate the pre-
dictive performance of the exhaled markers of inflammation [23]. KNN is a non parametric
lazy learning algorithm that uses vectors of predictors or covariates as training samples, each
with a class label. The training phase of the algorithm consists only of storing the feature vec-
tors and class labels of the patients in the training dataset. The KNN algorithm was imple-
mented using the SAS procedure DISCRIM.
Results
Patients
In the 2 participating hospitals, 331 children with doctor-diagnosed asthma were asked to par-
ticipate in the study. Of these children, 102 children and parents were willing to participate
(Fig. 1). These children were assessed for eligibility based on inclusion criteria. Six of these chil-
dren were excluded, because they could not perform dynamic spirometry maneuvers correctly
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(n = 1), did not meet the asthma criteria (n = 4) or had comorbidity with difficulty in distinc-
tion of symptoms between the diseases (n = 1).
96 children with asthma started the study. The majority of subjects was atopic and had se-
vere bronchial hyperresponsiveness despite a moderate daily dose of fluticasone (or equivalent)
(Table 2). There were no clinically relevant differences in baseline characteristics between the
centers. During the study 13 children dropped out. Of these children, 2 were excluded from the
statistical models because these children were only present during the first clinical visit and it
was unknown whether they experienced an exacerbation in the following 2 months (‘intention
to treat analysis’). No protocol deviations occurred.
Frequency of exacerbations
48% of all 94 children experienced 1or more exacerbations during the study. Of all exacerba-
tions 5 were severe in 5 children and 72 exacerbations were moderate.
Fig 1. Consort flow diagram of the study.
doi:10.1371/journal.pone.0119434.g001
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Description of exhaled markers of inflammation
The mean time between collection of EBC and occurrence of an asthma exacerbation was 33
days (standard deviation 17 days). In Table 3, the distribution of concentrations of FeNO, acid-
ity of EBC and EBC inflammatory markers is given. The inflammatory markers in EBC and
FeNO exhibited a large variability in concentrations as reflected by the wide ranges and IQR.
Predictive power of exhaled marker of inflammation
The results obtained from model 1 clearly illustrate that information on acidity of EBC and in-
flammatory markers in EBC alone are not suffice to carry out accurate predictions (Fig. 2). The
estimated parameters for this model are provided in Table 4. Notice that, although interesting
in an explanatory context, the point estimates and p-values are rather irrelevant in a prediction
context. More relevant in a prediction scenario is the area under the ROC-curve and for model
1 it was estimated as 47% (Fig. 2). The area under the ROC-curve of model 2, consisting of
FeNO and clinical characteristics was estimated as 54% (Fig. 2).
As expected, adding more predictors further improved the predictive performance of the
model. For instance, for the most complex model 3 the area under the curve equaled 59%
(Fig. 2). Nonetheless, the performance of all models was rather poor and the confidence inter-
val for the area under the curve contained the random guessing value 50% for all the models.
Similar results were obtained when the KNN algorithm was used. Similar to ROC-curves,
the most complex model 3 delivered the best prediction when using the KNN algorithm. In
fact, model 3 showed an overall correct prediction of 52% in the validation dataset (Table 5).
Table 2. Patient characteristics at baseline.
Total n = 96 Site A n =
51
Site B n =
45
Sex male, n (%) 50 (52) 27 (53) 23 (51)
Mean age [range] in years 10 [6 – 17] 9 [6 – 17] 10 [7 – 15]
FEV1% predicted value, mean ± SD 96.8 ± 14.2 95.4 ± 15.5 98.4 ± 12.7
Bronchodilator response, delta FEV1% predicted value:
mean ± SD
6.6 ± 8.5 6.7 ± 9.8 6.5 ± 7.0
ICS use, % 94 90 98
ICS Fluticasone daily dosage or equivalent, mean ± SD* 269 ± 175 295 ± 202 240 ± 134
ACQ, median [IQR] 0.6 [0.3–1] 0.5 [0.3–1.0] 0.6 [0.1–1.1]
FeNO, ppb: median [IQR] 12.5 [8.0–
31.0]
13.0 [8.0–
35.0]
12.0 [8.0–
27.0]
PC20, mg/mL: median [IQR] † 1.2 [0.3–2.9] 1.0 [0.3–2.3] 1.4 [0.4–3.2]
Atopic, %‡ 76 77 76
Site A = Maastricht, Site B = Sittard, FEV1 = forced expiratory volume in one second, SD = Standard
Deviation, ICS = Inhaled Corticosteroids, ACQ = Asthma Control Questionnaire, IQR = Inter Quartile
Range, PAQLQ = Pediatric Asthma Control Quality of Life Questionnaire, FeNO = Fractional exhaled Nitric
Oxide.
* Six children did not use ICS at baseline.
† PC20: concentration of histamine inducing a 20% drop in FEV1.
‡ Atopy is deﬁned as a positive Phadiatop (Phadia, Uppsala, Sweden), or RAST, or a positive allergen
skin test.
doi:10.1371/journal.pone.0119434.t002
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Table 3. Concentrations of inﬂammatory markers in EBC and FeNO.
Inﬂammatory markers n Minimum Maximum Median IQR
pH 611 3.31 8.80 5.80 5.52, 6.20
IL-1α, fg/ml* 619 0.30 23482.80 98.00 0.30, 483.20
IL-5, fg/ml 619 0.05 169.20 2.75 0.05, 19.33
IL-6, fg/ml 619 0.10 207.10 1.45 0.10, 21.20
IL-8, fg/ml 619 0.01 4508.51 0.01 0.01, 2.30
IL-13, fg/ml 619 0.05 393.80 4.43 0.05, 31.30
IL-17, fg/ml 619 0.15 1977.10 11.08 0.15, 184.53
TNFα, fg/ml 619 0.01 352.10 0.63 0.01, 11.45
FeNO, ppb 612 5.00 196.00 15.00 9.00, 27.00
IL = interleukin, TNF = tumor necrosis factor, FeNO = Fractional exhaled Nitric Oxide.
doi:10.1371/journal.pone.0119434.t003
Fig 2. Overview of ROC-curves of 3 predictivemodels for asthma exacerbations.ROC1: exacerbation
prediction model on the basis of the acidity of EBC and inflammatory markers in EBC alone; ROC2: model on
the basis of FeNO, reversibility to a bronchodilator as increase in FEV1% of predicted value, PC20, daily
dosage of ICS; ROC3: model all variables of model 1 and 2.
doi:10.1371/journal.pone.0119434.g002
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Discussion
In this study we investigated the prediction of asthma exacerbations in children by means of
exhaled inflammatory markers (acidity of EBC, inflammatory markers in EBC, FeNO) and
clinical asthma characteristics. Collection of EBC was successful in all children. The ability of a
combination of acidity of EBC and inflammatory markers in EBC and FeNO to predict asthma
exacerbations in children was poor. The prediction improved by the combination of exhaled
inflammatory markers and clinical characteristics (reversibility to a bronchodilator, PC20, daily
dosage of ICS). However, FeNO and clinical characteristics had no additional value on the pre-
dictive power of inflammatory markers in EBC. The AUC for the model with all the variables
was 59%, which was close to the level of 50% of random guessing. Thus, FeNO and inflamma-
tory markers in EBC assessments every 2 months, were not useful for the prediction of exacer-
bations in this study.
Neither acidity of EBC, inflammatory markers in EBC, FeNO, nor the combination of these
biomarkers was able to predict asthma exacerbations in children. Few studies have focused on
the ability of cytokines or chemokines in EBC to predict asthma exacerbations. Therefore, we
Table 4. Performance of acidity of EBC, inﬂammatory markers in EBC, FeNO, and asthma clinical characteristics in prediction of asthma
exacerbation.
Inﬂammatory markers estimate 95% CI p-value
pH 0.345 −0.029, 0.718 0.071
IL-1α −0.0004 −0.001, 0.0001 0.1
IL-5 0.014 −0.019, 0.047 0.394
IL-6 0.002 −0.015, 0.020 0.798
IL-8 −0.004 −0.012, 0.003 0.26
IL-13 −0.005 −0.018, 0.009 0.488
IL-17 −0.001 −0.002, 0.001 0.359
TNFα −0.001 −0.053, 0.051 0.96
FeNO −0.011 −0.029, 0.007 0.228
Atopy −0.182 −0.985, 0.620 0.656
PC20 −0.129 −0.347, 0.090 0.248
Bronchodilator response, delta FEV1 % predicted value −0.047 −0.104, 0.011 0.111
daily dosage of ICS −0.001 −0.003, 0.001 0.308
ACQ score 0.082 −0.424, 0.589 0.751
IL = interleukin, TNF = tumor necrosis factor, FeNO = Fractional exhaled Nitric Oxide, PC20 = histamine bronchial hyperresponsiveness test, FEV1 =
forced expiratory volume in one second, ICS = Inhaled Corticosteroids, ACQ = Asthma Control Questionnaire.
doi:10.1371/journal.pone.0119434.t004
Table 5. KNN- prediction of asthma exacerbation based on acidity of EBC, inﬂammatory markers in
EBC, FeNO, and asthma clinical characteristics. *
Exacerbation Prediction
No n(%) Yes n(%) Total n(%)
No 24 (33) 17 (24) 41 (57)
Yes 17 (24) 14 (19) 31 (43)
Total 41 (57) 31 (43) 72 (100)
* KNN algorithm is performed as statistical technique.
doi:10.1371/journal.pone.0119434.t005
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have compared our results with studies assessing related and/or distinct inflammatory markers
in EBC, or cytokines in BAL or sputum of children with asthma exacerbations.
First, we reviewed the studies which assessed the same EBC markers in exacerbations of
childhood asthma. Our finding of poor predictive capabilities of cytokines/chemokines in EBC
in this study is in contrast to findings of an earlier study[9]. Robroeks et al. reported that IL-5
in and the pH of EBC were predictors for exacerbations in 40 children with asthma in the
FLAME-study. There is considerable overlap between the FLAME-study and our study regard-
ing design, measurements and inclusion criteria. However, we were obliged to change the
chemical analysis of EBC and have applied another statistical method to build the predictive
model, which will be both discussed below. Second, we looked for published data regarding
markers of inflammation in EBC and exacerbations in asthma. Baraldi et al. compared cystei-
nyl leukotrienes (CysLTs) concentrations in EBC at the start of an asthma exacerbation in asth-
matic children, before and 5 days after prednisone treatment [24]. Equal to the cytokines in
our study, CysLTs are synthesized in the early-phase and late-phase asthmatic reaction. These
investigators reported a significant decrease of CysLTs after treatment with prednisone. Debley
et al. measured CysLTs in EBC in children during acute asthma exacerbations and 1, 2 and
4 weeks after hospital discharge [25]. As the EBC CysLT concentrations changed little during
1 month follow-up period, their findings suggest that EBC CysLT concentrations do not dis-
criminate between a stable period and an acute exacerbation [25]. In line with CysLTs, hydro-
gen peroxide, a marker for oxidative stress, was not significantly changed after treatment with
bronchodilators or oral steroids compared to during asthma exacerbation [26].
Third, regarding cytokine biomarkers in sputum samples, IL-8 and IL-5 concentrations
were assessed in (induced) sputum samples of asthmatic children during and 2 weeks after re-
covery of an acute asthma exacerbation [27]. In this study IL-5 was only detectable in 29% of
the sputum samples collected during asthma exacerbation and no significant change in IL-5
during the course of asthma exacerbation was found [27]. The low detection rate of IL-5 corre-
sponds to our finding that IL-5 has limited power to predict an asthma exacerbation. In con-
trast, IL-8 concentration was significantly reduced in sputum after recovery of the asthma
exacerbation, which was not reflected in our EBC analysis [27].
Fourth, our finding that FeNO could not predict an asthma exacerbation is in line with find-
ings of De Jongste et al. and by a meta-analysis by Petsky et al. [13, 28]. In the study of De
Jongste et al. in atopic asthmatics, daily FeNO measurements took place, which limited the
time span between FeNO measurements as much as possible [13]. However, even in this case
FeNO could not sufficiently predict an asthma exacerbation. In a recently performed RCT,
management based on FeNO levels had a positive effect on asthma outcome [29]. Although
these researchers found that significant less children in the FeNO group had 1 exacerbation
(s) compared to the control group, no statistically significant difference in exacerbation rate
was detected between the groups [29]. Therefore, our data and those of others suggest that
FeNO is not an useful predictor for asthma exacerbations in children.
A strength of this study was the focus on a combination of noninvasive inflammatory mark-
ers (inflammatory markers in EBC in combination with FeNO) along with clinical parameters
to predict asthma exacerbation in children using longitudinal assessments. Another strength
was the use of a home monitor for collection of daily symptom scores and lung function
(FEV1), in order to increase the chance to detect all exacerbations. Although we tried to keep
the design and methods in the FLAME-study and the current study comparable, 2 important
changes had to be made. First, the assay originally used to assess cytokines in EBC was no lon-
ger available. Therefore, we switched to a commercially available kit. Even though the original
assay was reliable, switching also implicated that our method could be more easily transferred
to other laboratories. Despite being sensitive, we were unable to reproduce the basic findings of
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the FLAME-study with the commercially available kit [9]. This may indicate that this kit is not
suitable for the EBC matrix and more effort has to be made to design assays suitable for EBC.
Second, we switched to another statistical method, namely conditionally specified models,
which is an advantage of the current study [22]. This type of model has progressed the past
years and takes into account the interdependency between repeated measurements within
1 child. In addition, 2 datasets were used for statistical analysis in the current study, namely a
training dataset (543 measurements) and a validation dataset (76 measurements), whereas in
the former FLAME-study only 1 dataset was analyzed with Cox regression. It is not likely that
switching models has affected the results of the current study.
We cannot exclude that we may have found different results if we had implemented shorter
time periods between regular visits. The time frame of 2 months was based on the design of the
FLAME-study in which we found significant results with 2-monthy intervals. With the ob-
served discrepancies between the studies, these time frames remain a matter of further investi-
gation. In a post hoc analysis based on results of daily FeNO measurements to predict an
asthma exacerbation in children, at least 3 to 5 FeNO measurements in the 3 weeks preceding
the exacerbation were needed to predict an exacerbation [30]. One single measurement was
not sufficient for prediction of an exacerbation. Overall, more work has to be done to deter-
mine the optimal time frame between an asthma exacerbation, and increase in parameters of
airway inflammation. Therefore, choosing a shorter time between visits may be more success-
ful, but may not be manageable for patients. Even in this study, patients dropped out because
clinical visits every 2 months proved too cumbersome.
There are several explanations for the low predictive capabilities of inflammatory markers
in EBC in this study. First, as mentioned, we have used commercially available hypersensitive
kits to analyze the EBC samples. Despite being sensitive, the detection of cytokines in EBC did
not meet expectations, which contributed to the poor predictive properties of the mediators.
Second, the exhaled markers of inflammation behaved similarly in a period without exacerba-
tions versus a period before and during an exacerbation. This may be the consequence of the
large variability in concentrations of inflammatory markers in EBC. The variability could be
influenced by: a) lack of sensitivity of antibodies of the assays used for chemical analysis, or b)
lack of assays adjusted for use with EBC as matrix. The ICS daily dosage could not mask possi-
ble predictive properties of the inflammatory markers, because this clinical parameter was in-
cluded in all predictive models.
So far neither assessment of biomarkers in EBC nor FeNO measurements, should be imple-
mented in clinical care to predict an asthma exacerbation. Despite our findings, the non-inva-
sive character of the inflammatory markers and direct measurement of airway inflammation
keeps this approach attractive. More (methodological) research is needed 1) to develop EBC
adjusted assays; 2) to develop appropriate storage techniques for EBC to avoid negative effects
of the EBC matrix on the stability of cytokines (such as low pH). Similar to the dried blood
spot storage method, an alternative option may be to absorb and store EBC onto filter paper
and avoid negative effects of, for instance proteases [31]. To establish these goals, more collabo-
ration between researchers and industry is necessary and should be stimulated. Beside im-
provement of assays for inflammatory marker detection in EBC, new information regarding
the metabolomics approach of EBC is promising. Metabolomic profiles demonstrated to be
specific for severe asthma and to allow adequate discrimination from non-asthma patients [32,
33].
In conclusion, the power of FeNO and inflammatory markers in EBC separately or com-
bined, for prediction of an asthma exacerbation with the current methodology was low. The re-
sults from the former FLAME-study could not be reproduced in this external validation study.
This may be due to methodological problems associated with storage and analysis of EBC.
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There is an urgent need for improvement in the chemical analysis of inflammatory markers in
EBC.
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